These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1133166)

  • 41. Comparison of Plasma Protein Binding of Basic Drugs in Black and White Individuals.
    Edeki T; Dillon-Moore B; He N
    Am J Ther; 1996 Sep; 3(9):611-615. PubMed ID: 11862300
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of clofibrate and chlorophenoxy isobutyric aicd. I. Cross-over studies on human volunteers.
    Männistö PT; Tuomisto J; Jounela A; Penttilä O
    Acta Pharmacol Toxicol (Copenh); 1975 Apr; 36(4):353-65. PubMed ID: 1093358
    [No Abstract]   [Full Text] [Related]  

  • 43. [Metabolism of plasma proteins and nephrotic syndrome].
    McFARLANE AS
    Brux Med; 1958 Oct; 38(41):1669-78. PubMed ID: 13584935
    [No Abstract]   [Full Text] [Related]  

  • 44. The molecular weights of the proteins of normal and nephrotic sera and nephrotic urine, and a comparison of selective ultrafiltrates of serum proteins with urine proteins.
    ROWE DS
    Biochem J; 1957 Nov; 67(3):435-45. PubMed ID: 13479401
    [No Abstract]   [Full Text] [Related]  

  • 45. Disposition pharmacokinetics of bezafibrate in man.
    Abshagen U; Bablok W; Koch K; Lang PD; Schmidt HA; Senn M; Stork H
    Eur J Clin Pharmacol; 1979 Aug; 16(1):31-8. PubMed ID: 499297
    [No Abstract]   [Full Text] [Related]  

  • 46. Plasma concentrations and bioavailability of clofibrate after administration to human subjects.
    Chasseaud LF; Cooper AJ; Saggers VH
    J Clin Pharmacol; 1974 Jul; 14(7):382-6. PubMed ID: 4845394
    [No Abstract]   [Full Text] [Related]  

  • 47. Plasma levels and pharmacokinetics of sulphinpyrazone in renal impairment during chronic treatment: a case report.
    Godbillon J; Schoeller JP; Gauron S; Gosset G; Fillastre JP
    Br J Clin Pharmacol; 1984 Jul; 18(1):107-8. PubMed ID: 6743484
    [No Abstract]   [Full Text] [Related]  

  • 48. [Intestinal plasma protein loss (protein diarrhea) in the nephrotic syndrome].
    KLUTHE R; LIEM HH; NUSSLE D; BARANDUN S
    Klin Wochenschr; 1963 Jan; 41():15-18. PubMed ID: 14033697
    [No Abstract]   [Full Text] [Related]  

  • 49. Hypoalbuminemia and Pharmacokinetics: When the Misunderstanding of a Fundamental Concept Leads to Repeated Errors over Decades.
    Gandia P; Decheiver S; Picard M; Guilhaumou R; Baklouti S; Concordet D
    Antibiotics (Basel); 2023 Mar; 12(3):. PubMed ID: 36978382
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug protein binding and the nephrotic syndrome.
    Gugler R; Azarnoff DL
    Clin Pharmacokinet; 1976; 1(1):25-35. PubMed ID: 797490
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease.
    Keller F; Maiga M; Neumayer HH; Lode H; Distler A
    Eur J Drug Metab Pharmacokinet; 1984; 9(3):275-82. PubMed ID: 6519129
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical pharmacokinetics of phenytoin.
    Richens A
    Clin Pharmacokinet; 1979; 4(3):153-69. PubMed ID: 383353
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Displacement of valproic acid and carbamazepine from protein binding in normal and uremic sera by tolmetin, ibuprofen, and naproxen: presence of inhibitor in uremic serum that blocks valproic acid-naproxen interactions.
    Dasgupta A; Volk A
    Ther Drug Monit; 1996 Jun; 18(3):284-7. PubMed ID: 8738769
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interactions of valproic acid with carbamazepine and its metabolites' concentrations, concentrations ratios, and level/dose ratios in epileptic children.
    Liu H; Delgado MR; Browne RH
    Clin Neuropharmacol; 1995 Feb; 18(1):1-12. PubMed ID: 8665529
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
    Ando Y; Nishiyama H; Shimodaira H; Takano N; Sakaida E; Matsumoto K; Nakanishi K; Sakai H; Tsukamoto S; Komine K; Yasuda Y; Kato T; Fujiwara Y; Koyama T; Kitamura H; Kuwabara T; Yonezawa A; Okumura Y; Yakushijin K; Nozawa K; Goto H; Matsubara T; Hoshino J; Yanagita M;
    Int J Clin Oncol; 2023 Oct; 28(10):1315-1332. PubMed ID: 37453935
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Systematic Review of Prophylactic Anticoagulation in Nephrotic Syndrome.
    Lin R; McDonald G; Jolly T; Batten A; Chacko B
    Kidney Int Rep; 2020 Apr; 5(4):435-447. PubMed ID: 32274450
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Off-label use of tacrolimus in children with glomerular disease: Effectiveness, safety and pharmacokinetics.
    Hao GX; Song LL; Zhang DF; Su LQ; Jacqz-Aigrain E; Zhao W
    Br J Clin Pharmacol; 2020 Feb; 86(2):274-284. PubMed ID: 31725919
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy.
    Reynolds ML; Nachman PH; Mooberry MJ; Crona DJ; Derebail VK
    J Nephrol; 2019 Aug; 32(4):669-672. PubMed ID: 30421320
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Population pharmacokinetics of tacrolimus in children with nephrotic syndrome.
    Hao GX; Huang X; Zhang DF; Zheng Y; Shi HY; Li Y; Jacqz-Aigrain E; Zhao W
    Br J Clin Pharmacol; 2018 Aug; 84(8):1748-1756. PubMed ID: 29637588
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome.
    Schijvens AM; Ter Heine R; de Wildt SN; Schreuder MF
    Pediatr Nephrol; 2019 Mar; 34(3):389-403. PubMed ID: 29549463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.